Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Zapater-Hernandez, P
  • Geronimo-Pardo, M

Abstract

The pharmacokinetic profile of intravenous acetaminophen administered to critically ill multiple-trauma patients was studied after 4 consecutive doses of 1 g every 6 hours. Eleven blood samples were taken (predose and 15, 30, 45, 60, 90, 120, 180, 240, 300, and 360 minutes postdose), and urine was collected (during 6-hour intervals between doses) to determine serum and urine acetaminophen concentrations. These were used to calculate the following pharmacokinetic parameters: maximum and minimum concentrations, terminal half-life, area under serum concentration-time curve from 0 to 6 hours, mean residence time, volume of distribution, and serum and renal clearance of acetaminophen. Daily doses of acetaminophen required to obtain steady-state minimum (bolus dosing) and average plasma concentrations (continuous infusion) of 10 g/mL were calculated (10 g/mL is the presumed lower limit of the analgesic range). Data are expressed as median [interquartile range]. Twenty-two patients were studied, mostly young (age 44 [34-64] years) males (68%), not obese (weight 78 [70-84] kg). Acetaminophen concentrations and pharmacokinetic parameters were these: maximum concentration 33.6 [25.7-38.7] g/mL and minimum concentration 0.5 [0.2-2.3] g/mL, all values below 10 g/mL and 8 below the detection limit; half-life 1.2 [1.0-1.9] hours; area under the curve for 6 hours 34.7 [29.7-52.7] g<bold>h</bold>/mL; mean residence time 1.8 [1.3-2.6] hours; steady-state volume of distribution 50.8 [42.5-66.5] L; and serum and renal clearance 28.8 [18.9-33.7] L/h and 15 [11-19] mL/min, respectively. Theoretically, daily doses for a steady-state minimum concentration of 10 g/mL would be 12.2 [7.8-16.4] g/day (166 [112-202] mg/[kg<bold>day</bold>]); for an average steady-state concentration of 10 g/mL, they would be 6.9 [4.5-8.1]g/day (91 [59-111] mg/[kg<bold>day</bold>]). In conclusion, administration of acetaminophen at the recommended dosage of 1 g per 6 hours to critically ill multiple-trauma patients yields serum concentrations below 10 g/mL due to increased elimination. To reach the 10 g/mL target, and from a strictly pharmacokinetic point of view, continuous infusion may be more feasible than bolus dosing. Such a change in dosing strategy requires appropriate, pharmacokinetic-pharmacodynamic and specific safety study.

Datos de la publicación

ISSN/ISSNe:
0091-2700, 1552-4604

JOURNAL OF CLINICAL PHARMACOLOGY  WILEY

Tipo:
Article
Páginas:
1345-1352
PubMed:
28419483
Factor de Impacto:
0,997 SCImago
Cuartil:
Q2 SCImago

Citas Recibidas en Web of Science: 4

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • acetaminophen pharmacokinetics; acetaminophen administration and dosage; intensive care; multiple trauma; human

Campos de Estudio

Proyectos y Estudios Clínicos

RED DE INVESTIGACION COOPERATIVA DE CANCER

RD06/0020/0031 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2006

ESTUDIO DE LA EXPRESION Y MECANISMOS MODIFICADORES DE LA ACTIVIDAD DE B-MYB Y C-MYB EN NEOPLASIAS MIELOIDES. IDENTIFICACION DE SUS GENES DIANA E IMPLICACION EN LA LEUCEMOGENESIS.

ACIF/2011/189 . FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2011

RED TEMATICA DE INVESTIGACION COOPERATIVA EN CANCER (RTICC)

Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO

RD12/0036/0014 . INSTITUTO DE SALUD CARLOS III . 2013

PRIMER ESTUDIO EN PERSONAS CON MEN1112, UN ANTICUERPO MONOCLONAL DIRIGIDO A CD157 EN LEUCEMIA MIELOIDE AGUDA EN RECAÍDA O REFRACTARIA.

Investigador Principal: PAU MONTESINOS FERNÁNDEZ

ARMY-1 . 2015

ESTUDIO ABIERTO Y DE UN SOLO GRUPO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE ABT-493/ABT-530 EN ADULTOS QUE HAN SIDO RECEPTORES DE UN TRASPLANTE HEPÁTICO O RENAL, CON INFECCIÓN CRÓNICA POR EL VIRUS DE LA HEPATITIS C (VHC) GENOTIPOS 1-6 (MAGELLAN-2).

Investigador Principal: MARTÍN PRIETO CASTILLO

M13-596 . 2016

ESTUDIO DE FASE I, INTERNACIONAL, MULTICÉNTRICO, ABIERTO, NO ALEATORIZADO Y NO COMPARATIVO DE S64315, UN INHIBIDOR MCL-1 ADMINISTRADO DE FORMA INTRAVENOSA, EN PACIENTES CON LEUCEMIA MIELOIDE AGUDA (LMA) O SÍNDROME MIELODISPLÁSICO (SMD).

Investigador Principal: PAU MONTESINOS FERNÁNDEZ

CL1-64315-001 . 2017

ESTUDIO DE FASE III MULTICÉNTRICO, RANDOMIZADO, CONTROLADO CON PLACEBO DE ATEZOLIZUMAB (ANTICUERPO ANTI#PD-L1) EN MONOTERAPIA Y EN COMBINACIÓN CON QUIMIOTERAPIA BASADA EN PLATINO EN PACIENTES CON CARCINOMA UROTELIAL LOCALMENTE AVANZADO O METASTÁSICO NO TRATADO PREVIAMENTE.

Investigador Principal: REGINA GIRONÉS SARRIÓ

WO30070 . 2017

ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, FASE 3, DE VENETOCLAX EN COMBINACIÓN CON AZACITIDINA EN COMPARACIÓN CON AZACITIDINA, EN PACIENTES CON LEUCEMIA MIELOIDE AGUDA NO TRATADOS ANTERIORMENTE Y NO ELEGIBLES PARA TERAPIAS DE INDUCCIÓN ESTÁNDAR.

Investigador Principal: PAU MONTESINOS FERNÁNDEZ

M15-656 . 2017

Cita

Compartir